Form 4: bioAffinity Technologies COO Acquires and Disposes of Shares
SEC Form 4 Filing
Xavier Trinidad Reveles, COO of bioAffinity Technologies, reports acquisition and disposal of common stock on January 10, 2025.
Summary
- On January 10, 2025, Xavier Trinidad Reveles, the Chief Operating Officer of bioAffinity Technologies, Inc. (BIAF), engaged in transactions involving the company's common stock.
- Reveles acquired 21,604 shares of common stock.
- Simultaneously, Reveles disposed of an unspecified amount of shares.
- Following these transactions, Reveles directly owns 41,943 shares of bioAffinity Technologies.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions by a company insider.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Stakeholder Impact
- Shareholders may be interested in the insider's transactions as an indicator of management's view of the company's stock value.
Key Dates
| Date | Description |
|---|---|
| 01/10/2025 | Date of transaction: acquisition and disposal of common stock. |
| 01/14/2025 | Date of signature on the Form 4 filing. |
| 02/10/2025 | Vesting start date for restricted shares, vesting monthly over 12 months. |
Keywords
bioAffinity Technologies, BIAF, Xavier Trinidad Reveles, Form 4, Insider Trading, Common Stock, Securities Exchange Act, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.